Research brief • May 13, 2026
Retatrutide “GLP-3” and MOTS-c Research Brief
Retatrutide and MOTS-c are both showing up in peptide conversations, but they represent two very different evidence stories. Retatrutide is an investigational triple-receptor agonist moving through human clinical trials. MOTS-c is a mitochondrial-derived peptide studied mainly through mechanism, cell, animal, observational, exercise, and early clinical research.
Save the COA and claim-checking prompts.
Get education-first checklists before you evaluate supplier pages or social claims.
Why this became today’s video-to-blog topic
The midnight video batch paired five short angles around the same theme: online peptide hype often compresses different kinds of research into one simple label. Retatrutide is often nicknamed “GLP-3” online because it targets three hormone-related receptor pathways. MOTS-c trends for a different reason: it sounds like a mitochondrial metabolism story, and social posts often turn early mechanism data into stronger claims than the evidence can support.
The goal for readers is not to chase a trend. It is to separate the category, the trial stage, the endpoints studied, and the quality of evidence behind each claim.
The short version
- Retatrutide, also known as LY3437943, is being studied as a GIP, GLP-1, and glucagon receptor agonist.
- “GLP-3” is social-media shorthand, not the formal scientific name or an approved consumer category.
- Published retatrutide studies include Phase 2 work in obesity, type 2 diabetes, and metabolic liver-disease endpoints, with additional trials listed in registries.
- MOTS-c is a mitochondrial-derived peptide studied around cellular metabolism, stress response, exercise biology, and aging-related mechanisms.
- Retatrutide has a much more mature human clinical-trial footprint than MOTS-c; MOTS-c remains more mechanism-first and exploratory.
Retatrutide: what “triple agonist” means
Retatrutide is designed to interact with three receptor systems: GIP, GLP-1, and glucagon. That is why online posts sometimes call it “GLP-3.” The phrase can be useful as shorthand, but it can also blur the actual science. Retatrutide is not simply “the third GLP.” It is an investigational multi-receptor drug candidate being evaluated through clinical trials.
Fresh source checks today found ClinicalTrials.gov listings for retatrutide across several research questions, including type 2 diabetes, kidney function, pharmacokinetics, body composition, and obesity-related protocols. Published PubMed-indexed papers include Phase 2 obesity and diabetes trials, plus metabolic dysfunction-associated steatotic liver disease research. Those sources support one careful conclusion: retatrutide is a serious clinical-development story, but it still depends on trial readouts, regulator review, safety data, and clear labeling before broad claims are justified.
MOTS-c: the mitochondrial peptide angle
MOTS-c is discussed in the literature as a mitochondrial-derived peptide. Researchers have studied it in relation to metabolic homeostasis, skeletal muscle biology, cellular stress response, exercise-related signaling, and disease-associated models. That makes it interesting for research literacy, but interest is not the same as a proven intervention.
Today’s ClinicalTrials.gov check showed MOTS-c appearing in a smaller and more scattered set of trial contexts than retatrutide. PubMed searches also show a broad mechanism-heavy literature, including newer work in cell and animal models. For readers, the key distinction is translation: a pathway signal in a model does not automatically become a safe, effective, or approved human use.
Evidence quality: the practical comparison
Retatrutide
Clinical-development evidence: human trials, defined populations, measured endpoints, adverse-event reporting, and trial registries. Watch for Phase 3 readouts and regulatory decisions.
MOTS-c
Mechanism-first evidence: mitochondrial signaling, metabolic pathways, cell and animal research, observational signals, and early human exploration. Watch for controlled human endpoints.
Social posts
Often merge “studied,” “trending,” “available,” “approved,” and “recommended.” Those are different claims and should be checked separately.
Reader filter
Ask: Is this a primary source? What population was studied? What endpoint was measured? Was it a trial, review, animal study, or marketing claim?
What to watch next
For retatrutide, the next meaningful checkpoints are larger Phase 3 data, comparator studies, body-composition results, cardiometabolic and kidney outcomes, tolerability patterns, and regulator-facing updates. For MOTS-c, the important developments would be well-controlled human trials that define specific endpoints without stretching mechanism data into broad claims.
Peptide Daily Report will continue tracking both topics with the same rule: explain what the studies say, what they do not say, and where online claims move beyond the evidence.
Research-only supplier note
If readers evaluate any research supplier, the responsible questions are documentation, posted testing, COA transparency, labeling clarity, and legal/regulatory fit. This is not a recommendation to purchase, use, dose, inject, or combine any compound.
Affiliate disclosure: I may earn a commission. Educational content only — not medical advice.
Sources checked
- PubMed — Retatrutide Phase 2 obesity trial, NEJM, 2023
- PubMed — Retatrutide Phase 2 type 2 diabetes trial, Lancet, 2023
- PubMed — Retatrutide metabolic dysfunction-associated steatotic liver disease Phase 2a trial, 2024
- ClinicalTrials.gov — Retatrutide trial registry search
- PubMed — MOTS-c metabolic homeostasis paper, 2015
- PubMed — Exercise and circulating mitochondrial-derived peptides in humans, 2021
- ClinicalTrials.gov — MOTS-c trial registry search
Keep learning
For plain-English peptide research notes, trial updates, and claim-checking frameworks, start with the Peptide Daily Report guide and follow the daily research briefs.
Get the free research kit.
COA prompts, supplier due-diligence notes, and article drops. No dosing, protocols, or medical advice.